Wai Yuen Tong Medicine Holdings Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Wai Yuen Tong Medicine Holdings.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 11.1% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Low P/S No Reason For Excitement
Nov 19
Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Share Price Boosted 51% But Its Business Prospects Need A Lift Too
Jul 26Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding
Mar 11The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business
Dec 28Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?
Jul 11Wai Yuen Tong Medicine Holdings (HKG:897) Takes On Some Risk With Its Use Of Debt
Jul 05Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?
Mar 08Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now
Aug 18Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Mar 17Wai Yuen Tong Medicine Holdings' (HKG:897) Shareholders Are Down 75% On Their Shares
Jan 22Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Dec 16
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wai Yuen Tong Medicine Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2024 | 784 | -27 | 157 | 192 | N/A |
| 9/30/2023 | 1,359 | 36 | 173 | 233 | N/A |
| 6/30/2023 | 1,323 | 8 | 153 | 199 | N/A |
| 3/31/2023 | 724 | -16 | 135 | 168 | N/A |
| 12/31/2022 | 1,314 | -98 | 149 | 182 | N/A |
| 9/30/2022 | 1,341 | -176 | 165 | 199 | N/A |
| 6/30/2022 | 1,366 | -143 | 154 | 184 | N/A |
| 3/31/2022 | 1,391 | -109 | 143 | 169 | N/A |
| 12/31/2021 | 1,323 | -122 | 142 | 182 | N/A |
| 9/30/2021 | 1,255 | -135 | 141 | 194 | N/A |
| 6/30/2021 | 1,182 | -255 | 247 | 303 | N/A |
| 3/31/2021 | 1,109 | -376 | 353 | 413 | N/A |
| 12/31/2020 | 979 | -98 | 282 | 321 | N/A |
| 9/30/2020 | 849 | 179 | 211 | 229 | N/A |
| 6/30/2020 | 735 | 309 | 86 | 98 | N/A |
| 3/31/2020 | 621 | 439 | -39 | -33 | N/A |
| 12/31/2019 | 655 | 253 | -65 | -54 | N/A |
| 9/30/2019 | 689 | 66 | -91 | -76 | N/A |
| 6/30/2019 | 720 | 71 | -68 | -51 | N/A |
| 3/31/2019 | 751 | 75 | -44 | -27 | N/A |
| 12/31/2018 | 779 | 20 | -86 | -52 | N/A |
| 9/30/2018 | 807 | -35 | -128 | -77 | N/A |
| 6/30/2018 | 826 | -75 | -134 | -77 | N/A |
| 3/31/2018 | 846 | -116 | -140 | -77 | N/A |
| 12/31/2017 | 808 | -106 | N/A | -61 | N/A |
| 9/30/2017 | 770 | -96 | N/A | -46 | N/A |
| 6/30/2017 | 754 | -94 | N/A | -68 | N/A |
| 3/31/2017 | 738 | -93 | N/A | -90 | N/A |
| 12/31/2016 | 769 | -87 | N/A | -65 | N/A |
| 9/30/2016 | 799 | -81 | N/A | -41 | N/A |
| 6/30/2016 | 812 | -28 | N/A | -78 | N/A |
| 3/31/2016 | 825 | 25 | N/A | -116 | N/A |
| 9/30/2015 | 827 | 177 | N/A | -93 | N/A |
| 6/30/2015 | 829 | 149 | N/A | -18 | N/A |
| 3/31/2015 | 831 | 121 | N/A | 58 | N/A |
| 9/30/2014 | 835 | 120 | N/A | 39 | N/A |
| 6/30/2014 | 850 | 144 | N/A | 27 | N/A |
| 3/31/2014 | 865 | 168 | N/A | 15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 897's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 897's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 897's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 897's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 897's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 897's Return on Equity is forecast to be high in 3 years time